Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I-IIA cutaneous melanomaEur. J. Cancer 2023 Jan 07;182(2023)77-86, S Meyer, L Buser, S Haferkamp, M Berneburg, T Maisch, M Klinkhammer-Schalke, A Pauer, T Vogt, C Garbe
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.